ArticleACS medicinal chemistry letters2019
Modifications at Arg and Ile Give Neurotensin(8-13) Derivatives with High Stability and Retained NTS
Article in ACS medicinal chemistry letters, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Advances in neurotensin receptor 1-targeted molecular probes for tumor molecular imaging and therapy.Frontiers in oncology · 2026Review
- High-Affinity and Proteolytically Stable Peptidic Fluorescent NTSJournal of medicinal chemistry · 2025Article
- Dually Labeled Neurotensin NTSJournal of medicinal chemistry · 2024Article
- Toward Stability Enhancement of NTSPharmaceutics · 2023Article
- Neurotensin and Alcohol Use Disorders: Towards a Pharmacological Treatment.International journal of molecular sciences · 2023Review
- Insertion of Nanoluc into the Extracellular Loops as a Complementary Method To Establish BRET-Based Binding Assays for GPCRs.ACS pharmacology & translational science · 2022Article
- Development of a Neurotensin-DerivedCancers · 2022Article
- Neurotensin analogs by fluoroglycosylation at NScientific reports · 2022Article
- Optimized Opioid-Neurotensin Multitarget Peptides: From Design to Structure-Activity Relationship Studies.Journal of medicinal chemistry · 2020Article
- Optimizing the Profile of [International journal of molecular sciences · 2020Article
- Key-Protease Inhibition Regimens Promote Tumor Targeting of Neurotensin Radioligands.Pharmaceutics · 2020Article
- An Alkyne-functionalized Arginine for Solid-Phase Synthesis Enabling "Bioorthogonal" Peptide Conjugation.ACS medicinal chemistry letters · 2020Article
- Fluorescence Labeling of Neurotensin(8-13) via Arginine Residues Gives Molecular Tools with High Receptor Affinity.ACS medicinal chemistry letters · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Due to its expression in various malignant tumors, the neurotensin receptor 1 (NTS
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.